On August 25, 2008, at a townhall meeting in Hazleton, Pennsylvania, the United States Agency for Toxic Substances and Disease Registry (ATSDR) announced that, after a year of investigation, it has confirmed the existence of 33 cases of a rare type of cancer in an isolated region in northeast Pennsylvania. http://www.atsdr.cdc.gov/NEWS/pv_08252008.html
The American Medical Association (AMA) is ramping up its efforts to stifle the stigma of impropriety among consumer advocates and patient groups, by proposing to add specific guidelines requiring physicians to disclose their financial ties to the pharmaceutical and medical device industry with patients.
Use of the cholesterol drugs Zocor (Simvastatin), Zetia (Ezetimibe), and Vytorin (Simvastatin + Ezetimibe) may be associated with an increased risk of some types of cancer.
On August 21, 2008, the FDA posted an alert on its website, advising that early results from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) clinical trial indicated not only that Vytorin appears to be ineffective in reducing overall cardiovascular risk, but that the drug may bring with it an increased risk of a variety of cancers, including skin cancer.
In typical fashion, the FDA’s communication, available at http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin_SEAS.htm, follows the language alerting of the SEAS results with language equivocating as to the accuracy of the results, stating that other larger studies have shown no link between cholesterol-lowering drugs and cancer.
Although the FDA advises that consumers should not stop taking these drugs, it does not expect final SEAS results for another 3 months and will take an additional 6 months to review those results.
If your doctor has advised you that your ingestion of a cholesterol lowering drug may have contributed to any form of cancer that you have developed and you would like to consult with an attorney, please visit our website at http://www.pbmattorneys.com, or call us directly at (888) 348-6787.
On August 8, 2008, the FDA issued a warning advising consumers who filled prescriptions at two Baltimore, Maryland pharmacies that the drugs they received from the pharmacies may have been counterfeit or expired. As the warning states, many of the suspected drugs, for which neither efficacy nor safety has been established by the FDA, are used for the treatment of serious conditions.
The two Baltimore pharmacies in question are in The Medicine Shoppe chain of pharmacies: one located at 8035A Liberty Road and one at 5900 Reistertown Road.
The full warning, and a listing of the suspected drugs, is available on the FDA’s website. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01873.html If you believe that you filled a prescription for one of the listed drugs and would like to consult with an attorney to determine whether or not you have a lawsuit, please visit us at our website, http://www.pbmattorneys.com , or call us directly at (888) 348-6787.
On August 15, 2008, the U.S. Food and Drug Administration (FDA) announced a Class 1 Recall of Boston Scientific’s NexStent Monorail, NexStent Carotid Stent, and Monorail delivery system “because the tip of the stent-delivery system may detach during the procedure.”
Yet another supposed “all natural” or “herbal” supplement for erectile dysfunction contains precisely the ingredient that frequent users are intending to avoid. After an FDA lab analysis of a sample of the Viapro revealed that it contained an undeclared and potentially harmful ingredient, thio-methisosildenafil, EG Labs, LLC, announced that it is recalling all lots of its supplement product in 375mg capsules. Thio-methisosildenafil is an analog of sildenafil, which is the active chemical ingredient of several FDA-approved drugs used for Erectile Dysfunction (ED) in men to enhance sexual performance.
On August 7, 2008, Respondent Diane Levine filed her brief in the United States Supreme Court in Wyeth v. Levine, 06-1249. The brief can be found here, Wyeth v. Levine, 06-1249, Brief for Respondent. For now, we’ll limit our commentary to an acknowledgment that the brief is a masterful rebuttal to Wyeth’s illusory approach at implied conflict preemption and the empty rhetoric in support of the wholesale banning of prescription drug lawsuits.
In an unprecedented decision, the Federal Communications Commission (FCC) recently affirmed its authority to protect a “vibrant and open Internet” by ordering Comcast to cease selective and preferential interference over some of its online subscribers, namely those customers whom share online files via peer-to-peer applications (P2P).
In a 2006 presentation at an American Academy of Orthopedic Surgeons meeting, evidence was presented that showed that the anesthetics contained in pain pumps used after shoulder surgery lead to Postarthroscopic Glenohumeral Chondrolysis (PAGCL). In fact, studies now suggest that up to 63% of arthroscopic shoulder surgery patients who receive a post-operative pain pump may develop PAGCL. The condition leads to a lifetime of suffering, has no consistently successful treatment, and often results in permanent shoulder pain, loss of mobility and further surgery, specifically shoulder replacement surgery.